Prospective CoHoRt Of Non-infectious Intermediate, pOsterior or panuveitiS
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: care strategy.
- Who it may be relevant to
- Registry conditions: Non-infectious Uveitis. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
prospective, cohort, longitudinal, multicenter, non-randomized study of patients with non-infectious posterior segment uveitis or panuveitis, with a group of control patients (scheduled for cataract or vitreoretinal surgery) and constitution of biological collection.
Detailed description
Description of the clinical characteristics and evolution in a large cohort of patients with non-infectious uveitis, allowing to identify prognostic or predictive factors of response after treatment of these different forms of non-infectious uveitis of the posterior segment or panuveitis (factors that are currently not well known).
Uveitis patients:
* Blood sample (20ml): Additional 20 ml blood sample during the first visit and potentially during follow-up (if necessary) for the purpose of the biological collection; * Ocular sample (aqueous humor, vitreous): if required by the clinical context for the needs of the biological collection; * Specific imaging: adaptive optics or Doppler holography, these procedures will be indicated on a case-by-case basis, at the investigator's discretion, and concern only patients with inflammatory vascular damage (5 to 10% of patients in the uveitis cohort); * Quality of Life NEI-VFQ 25: provided at the inclusion visit and at follow-up visits M3-V2, M12-V5 and M24-V7.
Control patients:
* Blood sample (20ml): Additional 20 ml blood sample during the inclusion visit at the time of the surgical scheduled procedure for the needs of the biological collection; * Ocular sample (aqueous humor, vitreous): considered as surgical waste, the tissue residues will be collected during the scheduled surgical procedure for cataract or vitreoretinal surgery for the needs of the biological collection;
Interventions
- Diagnostic test care strategy
Uveitis patients: * Blood sample (20ml): Additional 20 ml blood sample during the first visit and potentially during follow-up (if necessary) for the purpose of the biological collection; * Ocular sample (aqueous humor, vitreous): if required by the clinical context for the needs of the biological collection; * Specific imaging: adaptive optics or Doppler holography, these procedures will be indicated on a case-by-case basis, at the investigator's discretion, and concern only patients with infl
Primary outcome measures
- Imaging database development [Time frame: 60 months]
- Biological constitution [Time frame: 60 months]
- medico economic costs estimation [Time frame: 60 months]
Eligibility criteria
Inclusion criteria
UVEITIS Patients:
- Adult patients (≥ 18 years);
- Non-infectious uveitis;
- Intermediate, posterior or panuveitis;
- Inflammatory activity requiring treatment with either one or more of the followings:
- Systemic corticosteroids or periocular or intravitreal injections of corticosteroids;
- Immunosuppressants: methotrexate, azathioprine, cyclosporine, etc.;
- Biotherapy: infliximab, adalimumab, tocilizumab;
- Patients with health insurance;
- Written Informed consent obtained at enrolment in the study.
Control patients:
- Adult patients (≥ 18 years);
- Scheduled patients ( Non-urgente procedure) for cataract or vitreoretinal surgery;
- Patients with health insurance;
- Written Informed consent obtained at enrolment in the study.
Exclusion criteria
Uveitis Patients:
- Isolated anterior uveitis ;
- Inactive disease defined as:
- Absence of inflammatory chorioretinal and/or inflammatory retinal vascular lesion;
- Anterior chamber cell grade< 0.5+;
- Vitreous haze grade <0.5+;
- Pregnant or breastfeeding woman at the inclusion visit;
- Patient under legal protection (" curatelle " or " tutelle ");
- Patient denied freedom by a legal or administrative order.
Control patients:
- Pregnant or breastfeeding woman;
- Unscheduled (urgent) cataract or vitreoretinal surgery;
- Patient under legal protection (" curatelle " or " tutelle ");
- Patient denied freedom by a legal or administrative order.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Non-randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Diagnostic
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT05928754 · P22-01